
News|Videos|May 25, 2023
Changing the Paradigms of How We Think About Depression
Author(s)Greg Mattingly, MD
Check out this review of the 2023 APA Annual Meeting presentation on the efficacy and safety of repeat treatment courses using novel medicine, zuranolone.
Advertisement
CONFERENCE REPORTER
Greg Mattingly, MD, shares a review of the 2023 APA Annual Meeting presentation that covered long term results of the year long study on zuranolone in major depressive disorder.
Dr Mattingly is an associate clinical professor at Washington University School of Medicine, and is a physician and principal investigator in clinical trials for Midwest Research Group.
Newsletter
Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Psychiatric Times
1
Southern California Psychiatry: Review of New Agents in Schizophrenia and Dementia
2
Cobenfy for Treatment of Schizophrenia Now Approved in China
3
Programs for ST-905 and ST-905 for Schizophrenia and Depression Launched by Syremis Therapeutics
4
Latest Alzheimer Disease Data: Reports from CTAD 2025
5

















